Myeloperoxidase from neutrophils causes endothelial dysfunction and vascular inflammation.

Myeloperoxidase (MPO) is a heme-containing peroxidase enzyme that serves as a cornerstone of the innate immune response while simultaneously acting as a potent driver of chronic vascular damage. In individuals such as a 50-year-old female, MPO levels often serve as a significant biomarker for assessing cardiovascular risk and systemic inflammation.

Clinical and Mechanistic Evidence

Research confirms that MPO is primarily synthesized and stored in the azurophilic granules of neutrophils. Upon activation by inflammatory stimuli, these cells release MPO into the extracellular environment, where it initiates a cascade of oxidative reactions.

• Oxidative Catalysis: MPO utilizes hydrogen peroxide (H₂O₂) to produce hypochlorous acid (HOCl) and other reactive species. While these are essential for neutralizing pathogens, their presence in the vascular space leads to non-specific oxidative damage to host tissues.
• Nitric Oxide (NO) Depletion: A primary mechanism of endothelial dysfunction is MPO’s ability to reduce the bioavailability of nitric oxide. MPO directly consumes NO via its catalytic cycle and oxidizes soluble guanylyl cyclase (sGC), the enzyme responsible for translating NO signals into vasodilation.
• Enzymatic Inhibition: MPO further impairs vascular health by inhibiting endothelial nitric oxide synthase (eNOS) and reacting with L-arginine, the precursor required for NO synthesis. This depletion of NO leads to impaired endothelium-dependent vasodilation and increased vascular stiffness.

Vascular Inflammation and Atherogenesis

MPO acts as a bridge between innate immunity and the progression of vascular disease through several inflammatory pathways:

• LDL Modification: MPO modifies low-density lipoprotein (LDL) to create Mox-LDL, a highly pro-inflammatory and atherogenic form. This modification triggers scavenger receptors like LOX-1 on endothelial cells, promoting the recruitment of leukocytes and the formation of foam cells within the vessel wall.
• Subendothelial Infiltration: MPO possesses a strong cationic charge, allowing it to bind to the vessel wall and undergo transcytosis into the subendothelial matrix. Once embedded, it catalyzes the nitration of matrix proteins, perpetuating a state of chronic vascular inflammation and contributing to plaque instability.
• Adhesion Molecule Expression: The oxidative stress generated by MPO induces the expression of adhesion molecules (such as ICAM-1 and VCAM-1), which facilitates the migration of more neutrophils and monocytes into the vascular tissue, creating a self-sustaining cycle of inflammation.

Bottom line

The claim is fully supported: Myeloperoxidase is an oxidative enzyme released by neutrophils that directly causes endothelial dysfunction by depleting nitric oxide and promotes vascular inflammation through the modification of lipoproteins and matrix proteins. These mechanisms make MPO a critical mediator in the development and progression of cardiovascular disease.